Back to Browse Journals » Drug, Healthcare and Patient Safety » Volume 5

Clinical use of anti-TNF therapy and increased risk of infections

Authors Ali T, Kaitha S, Mahmood S, Ftesi A, Stone J, Bronze MS

Received 22 December 2012

Accepted for publication 11 February 2013

Published 28 March 2013 Volume 2013:5 Pages 79—99


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Tauseef Ali,1,2 Sindhu Kaitha,2 Sultan Mahmood,2 Abdul Ftesi,3 Jordan Stone,2 Michael S Bronze2

1OU Physicians Center for Inflammatory Bowel Disease, University of Oklahoma Health Sciences Center, 2Department of Internal Medicine, University of Oklahoma Health Sciences Center, 3Integris Baptist Hospital, Oklahoma City, Oklahoma, USA

Abstract: Biologics such as antitumor necrosis factor (anti-TNF) drugs have emerged as important agents in the treatment of many chronic inflammatory diseases, especially in cases refractory to conventional treatment modalities. However, opportunistic infections have become a major safety concern in patients on anti-TNF therapy, and physicians who utilize these agents must understand the increased risks of infection. A literature review of the published data on the risk of bacterial, viral, fungal, and parasitic infections associated with anti-TNF therapy was performed and the clinical presentation, diagnostic tests, management, and prevention of opportunistic infections in patients receiving anti-TNF therapy were reviewed. Awareness of the therapeutic potential and associated adverse events is necessary for maximizing therapeutic benefits while minimizing adverse effects from anti-TNF treatments. Patients should be adequately vaccinated when possible and closely monitored for early signs of infection. When serious infections occur, withdrawal of anti-TNF therapy may be necessary until the infection has been identified and properly treated.

Keywords: anti-TNF therapy, infections

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]


Readers of this article also read:

How bees distinguish patterns by green and blue modulation

Horridge A

Eye and Brain 2015, 7:83-107

Published Date: 5 October 2015

Antipsychotic agents: efficacy and safety in schizophrenia

de Araújo AN, de Sena EP, de Oliveira IR, Juruena MF

Drug, Healthcare and Patient Safety 2012, 4:173-180

Published Date: 29 November 2012

Analysis on descriptions of precautionary statements in package inserts of medicines

Nabeta K, Kimura M, Ohkura M, Tsuchiya F

Drug, Healthcare and Patient Safety 2012, 4:19-25

Published Date: 24 February 2012

Trigeminal neuralgia: successful antiepileptic drug combination therapy in three refractory cases

Prisco L, Ganau M, Bigotto F, Zornada F

Drug, Healthcare and Patient Safety 2011, 3:43-45

Published Date: 10 August 2011